synchronous and metachronous disease.

SRX website has some data that I've not seen before - not sure when it changed, but my Google agent reported it today.

Interestingly is the synchronous %



There was a broker report from Bell Potter some time ago suggesting that the patients that were selected for the trail were the 'hard cases' e.g. the Synchonous ones. The % at 90% suggests there may be some validity in the assertion.

From the NBI
'
RESULTS:

Discrete differences in tumour biology have been identified in separate studies. Twenty-one articles comparing outcomes were reviewed. Definitions of metachronicity varied from anytime after primary tumour evaluation to 1 year after surgery for primary tumour. Most studies reported that synchronous lesions were associated with poorer survival rates (8% to 16% reduction over 5 years). Sixteen articles comparing combined vs staged resections for synchronous tumour showed comparable morbidity and mortality. Benefits over staged resections included shorter hospital stays and earlier initiation of chemotherapy. Suitability for combined resection depended on patient age and constitution, primary tumour characteristics, size and the number of liver metastases, and the extent of liver involvement.
http://www.ncbi.nlm.nih.gov/pubmed/20957308

Do we have any oncologists that can comment?